# HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Source: https://onco.cc/trials/nct06770452/  
OnCo record `nct06770452` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nimotuzumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang University, now recruiting.

## Summary

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients is a phase 2, randomised interventional study registered as NCT06770452 by Zhejiang University, with a registry enrolment figure of 133 participants, started 2025-03-25 and due to reach its primary completion in 2027-02-01. Interventions recorded: HRS-4642; Nimotuzumab; gemcitabine + nab-paclitaxel. Conditions listed: Metastatic Pancreatic Carcinoma. Primary outcome: Objective reponse rate (ORR). Pancreatic eligibility wording from the registry: "Metastatic pancreatic cancer (from pancreatic ductal epithelium) for Arm A; Locally advanced pancreatic cancer (from pancreatic ductal epithelium) for Arm B; 3". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06770452
- Phase: 2
- Setting: A Single-arm Phase II Study of HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients With KRAS G12D Mutations
- Sponsor: Zhejiang University
- Enrolled: 133

## Sources

- ClinicalTrials.gov NCT06770452: https://clinicaltrials.gov/study/NCT06770452

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [Nimotuzumab](https://onco.cc/drugs/nimotuzumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06770452.json